Kornimate/medical-research-clean huggingface dataset:
the effect of fibromyalgia syndrome accompanying obstructive sleep apnea syndrome on clinical findings

Conditions: Obstructive Sleep Apnea; Fibromyalgia

Summary: fibromyalgia syndrome (fms) is a chronic disease that lasts for at least three months and is characterized by various symptoms such as tender points, widespread pain in the musculoskeletal system, sleep disturbance and fatigue. obstructive sleep apnea (osas) is a disease characterized by repeated upper airway obstruction during sleep. sleep disorders negatively affect the lives of individuals. the prevalence of osas is between 1-5% in studies and it is more common in men than in women. fatigue, anxiety, depression and sleep disturbance are also common in patients with fibromyalgia. likewise, the presence of symptoms such as musculoskeletal pain in patients with osas suggests that these two diseases may be related to each other. we planned this study to show the relationship between osas and fibromyalgia (fm).

our research will be carried out on patients diagnosed with osas after being evaluated in the sleep laboratory of the research hospital department of chest diseases. fibromyalgia screening will be performed on participants who are diagnosed with osas and accepted to participate in the study. patients with fm according to the 2010 american college of rheumatology diagnostic criteria will be divided into two groups as fm patients (case group) and patients who do not meet these criteria (control group). sleep laboratory results and demographic data of all patients will be recorded. in addition, anxiety, depression and fatigue levels will be evaluated with scales. fibromyalgia impact questionnaire will be applied to fibromyalgia patients. our study is a cross-sectional prospective case-control study. it is not a treatment research, an interventional application will not be made to the patients. our hypothesis is that osas patients with fms may have more fatigue, anxiety, depression, lower algometer values, and more severe osas findings in polysomnographic data.

Eligibility criteria:
inclusion criteria: 1.18-60 years old 2. diagnosed with osas in sleep laboratory examinations 3. agree to participate in the study exclusion criteria: 1. pregnancy 2. neuropsychiatric disease 3. inflammatory rheumatic diseases 4. morbid obesity 5. using a device with a previous diagnosis of osas

Keywords: polysomnography obstructive sleep apnea fibromiyalgia
to determine the efficacy and safety of dw1029m on microalbuminuria in patients with diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: phase 2 clinical study to evaluate of the efficacy and safety of dw1029m on microalbuminuria in patients with diabetic nephropathy

a phase ⅱ, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center clinical trial for the evaluation of the efficacy and safety of dw1029m on microalbuminuria in patients with diabetic nephropathy

Eligibility criteria:
inclusion criteria: * has confirmed diabetic mellitus prior to 6years * has confirmed microalbuminuria 30 \~ 299㎍/㎎creatinine prior to 5months one time and microalbuminuria 30 \~ 299㎍/㎎creatinine during screening period * blood pressure(bp) ≤ 150 / 90 mmhg * estimated glomerular filtration rate(egfr) ≥ 30 ml/min/1.73m2 * hemoglobin a1c(hba1c) ≤ 9% * low density lipoprotein(ldl-c) ≤ 130mg/dl exclusion criteria: * kidney or liver disease as follows i.serum creatinine \> 2.0mg/dl ii.alanine aminotransferase(alt) or aspartate aminotransferase(ast) \> 2 x upper limit normal(uln) iii.total bilirubin \> 2 x uln * organic gastrointestinal disorder or chronic gastroenterologic disorders prior to 6 months as follows \[note\] active crohn's disease, active ulcerative colitis, chronic peptic ulcer disease, etc. * cardiovascular disease prior to 3 months as follows \[note\] unstable angina pectoris, myocardial infarction, coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, transient ischemic attack, cerebrovascular accident etc.

Keywords: microalbuminuria
special use - results surveillance on long-term use with wegovy®

Conditions: Obesity

Summary: the purpose of the study is to investigate the safety and effectiveness of wegovy® in patients with obesity disease under real-world clinical practice in japan. participants will get wegovy® as prescribed by the study doctor. the study will last for about 4 years. participant will be in the study for about 2 years (104 weeks).


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * the decision to initiate treatment with commercially available wegovy® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study * male or female, no age limitation * diagnosis of obesity disease; with either hypertension, dyslipidaemia or type 2 diabetes, insufficiently controlled with diet and exercise therapies, and should meet either of: 1. body mass index (bmi)\* greater than or equal to 27 kilograms per meter square (kg/m\^2) with two or more obesity-related comorbidities\*\*, or 2. bmi\* greater than or equal to 35 kg/m\^2 * participant who has never been exposed to semaglutide or who started treatment with wegovy® within the past 4 weeks at registration * bmi calculation will be based on height and body weight recorded in the enrolment form of electronic case report form (ecrf) at enrolment. * definition of obesity-related comorbidities are in accordance with japan student services organization (jasso) guideline 3: (1) impaired glucose tolerance, (2) dyslipidaemia, (3) hypertension, (4) hyper-uricemia/gout, (5) coronary artery disease, (6) cerebral infarction, (7) non-alcoholic fatty liver disease, (8) menstrual disorder/infertility, (9) obstructive sleep apnoea syndrome/obesity-hypoventilation syndrome, (10) locomotory disease or (11) obesity-related kidney disease. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * treatment with any investigational drug within 30 days prior to baseline (visit 1) * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * a history of hypersensitivity to any ingredients of this drug * diabetic ketoacidosis, diabetic coma, pre-coma or type 1 diabetes mellitus \[the treatment with insulin is mandatory. it is not appropriate to use this drug\] * in emergency cases such as severe infections and surgery in patients with type 2 diabetes \[it is desirable to control blood glucose with insulin; therefore, administration of this drug is not appropriate\] * pregnant or possibly pregnant female * female who plans to become pregnant within 2 months
tai chi training on hand grip strength and functional fitness in post covid

Conditions: Post Covid

Summary: to evaluate the effects of participating of tai chi program on hand grip strength and functional fitness in post covid

evaluate the effects of tai chi and aerobic training on improving hand grip strength, fatigue, and functional fitness in patients with post covid-19.

Eligibility criteria:
inclusion criteria: * post covid exclusion criteria: * medically unstable * post stroke * obese * mentally unstable
evaluation of immediate implant placement in the esthetic zone using the bone shielding concept versus dual zone therapy

Conditions: Immediate Implants; Alveolar Bone Loss; Dual Zone Technique; the Bone Shielding Concept; Esthetic Zone

Summary: immediate implant placement has proven to be a successful treatment procedure that is preferred by patients because of being less traumatic, more time-efficient. nowadays, the main goal of a successful immediate implant treatment has ceased to be gaining stability and osseointegration, but achieving long-term dimensional stability has become the optimal challenge. various soft tissue and hard tissue augmentation techniques have been investigated in order to maintain the ridge dimensions following extraction and immediate implant placement.

it has been noted that the different augmentation procedures aid in decreasing the dimensional changes occurring after immediate implant placement in the esthetic zone. even though immediate implant placement is a predictable procedure, however, labial bone resorption following tooth extraction is inevitable. the available surgical techniques present do not entirely prevent dimensional variations of the peri-implant hard and soft tissues over time. furthermore, substantial evidence showed that immediate implant placement failed to halt the resorption of the thin buccal bony plate with subsequent gingival recession, particularly in patients with thin gingival phenotype

Eligibility criteria:
inclusion criteria: * adult (\>18 years) patients having a single non-adjacent hopeless maxillary tooth in the esthetic zone * type i socket (intact but thin labial plate of bone and intact overlying soft tissues) * adequate palatal bone * ≥3 mm apical bone to engage the immediately placed implants * optimum primary stability (a minimum of 30 ncm insertion torque) following tooth extraction. exclusion criteria: * smokers * pregnant women * patients with systemic diseases * periodontal disease, gingival recession * infected sockets * periapical pathosis and history of chemotherapy or radiotherapy within the past 2 years.

Keywords: esthetic zone soft tissue augmentation
a study of ro5024048 in combination with pegasys (peginterferon alfa-2a) and copegus (ribavirin) in patients with chronic hepatitis c genotype 1 or 4

Conditions: Hepatitis C, Chronic

Summary: this equally randomized (1:1), double-blind, parallel arm study will assess the safety and antiviral efficacy of ro5024048 added to standard pegasys (peginterferon alfa-2a) plus copegus (ribavirin) therapy in patients with chronic hepatitis c genotype 1 or 4. patients in arm a will receive ro5024048 (1000mg orally twice daily) for 24 weeks in addition to pegasys (180 micrograms sc weekly) and copegus (1000mg or 1200mg orally daily). patients achieving a rapid virological response (rvr) at week 4, sustained through week 22, will stop all treatment at week 24; non-rvr patients will continue treatment with pegasys and copegus for another 24 weeks up to week 48. patients in arm b will receive standard treatment with pegasys (180 micrograms sc weekly) and copegus (1000mg or 1200mg orally daily) for 48 weeks. anticipated time on study treatment is up to 48 weeks. target sample size is \<200.


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age * hepatitis c, genotype 1 or 4, of over 6 months duration * treatment-naïve * negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin exclusion criteria: * pregnant or breast feeding females or male partners of pregnant females * previous interferon or ribavirin based therapy or investigational anti-hcv agent * systemic antiviral therapy with established or perceived activity against hcv \</=3 months prior to first dose of study drug * hepatitis a or b, or hiv infection * history or evidence of medical condition associated with chronic liver disease other than hcv
study of indiplon/placebo with sertraline in insomnia co-existing with depression

Conditions: Insomnia; Depression

Summary: the goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.

this pfizer run study stopped due to the co-development program for indiplon being terminated between pfizer and neurocrine. the study was terminated on 16 november 2006. there were no safety issues leading to the decision to terminate this study.

Eligibility criteria:
inclusion criteria: * dsm-iv defined insomnia * dsm-iv defined major depression exclusion criteria: * current suicidal ideation or behavior * primary sleep disorder other than insomnia
prospective double-blind study for the use of aspirin during transurethral surgery of the bladder or the prostate

Conditions: Blood Loss, Surgical; Intraoperative Complications; Re-operation Rates in Patients With Aspirin Treatment

Summary: aspirin is very common in older patients. therefore many of the investigators patients have aspirin. the aim of the study is to proof that transurethral surgery of the bladder or the prostate can be performed with aspirin.


Eligibility criteria:
inclusion criteria: * transurethral surgery of the bladder or prostate, informed consent, age over 18 exclusion criteria: * oral anticoagulation,

Keywords: aspirin blood loss transurethral surgery
epidural neostigmine for labor pain

Conditions: Labor Pain

Summary: the purpose of this study is to see which dose of epidural neostigmine is the best additive to use with the numbing medication used in an epidural during labor.

this study is examining the use of the non-narcotic medication, neostigmine, in combination with the local anesthetic bupivacaine when compared with the commonly used narcotic fentanyl in providing pain relief with the fewest side effects in labor analgesia.

Eligibility criteria:
inclusion criteria: * healthy pregnancy * term pregnancy ( \> 37 weeks) * primiparous or multiparous * induction or spontaneous labor greater or = 18 years of age * cervical exam on entry \</=5 cm exclusion criteria: * weight \> 115 kg * non-english speaking * iv analgesics within 60 minutes prior to epidural being administered * allergy to local anesthetics or neostigmine

Keywords: non narcotic epidural labor pain non narcotic treatment of labor pain
study of ph3 for the prevention of osteoporosis in postmenopausal women

Conditions: Osteoporosis

Summary: the primary objective of this clinical study is to evaluate the effectiveness and safety of ph3 for the prevention of osteoporosis. the secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.


Eligibility criteria:
inclusion criteria: 1. women 40-60 years of age. 2. must be postmenopausal (0.5\~5 years post cessation of menses) or ovariectomized or hysterectomy women who have documented elevated follicle stimulating hormone fsh (\>30miu/ml) with low serum estradiol (\<20 pg/ml). 3. the lumbar vertebral bmd t-score is between -1and -2.5 sd. 4. the body mass index (bmi) is between 19 and 29 kg/m2. 5. completed informed consent and signed informed consent form. exclusion criteria: 1. have diseases which may affect bone metabolism, e. g., hyper-or hypocalcemia, hyperthyroidism, osteogenesis imperfecta, malignancy, chronic gastrointestinal disease, extensive paget's disease, alcoholism, and renal or hepatic impairment. 2. has taken drug therapy for osteoporosis within the previous six months (excluding calcium supplements) prior to this study. 3. chronic or continued use of hormone replacement drugs or medications that may affect bone calcium metabolism, for example, phosphate-binding antacids, many diuretics, adrenal or anabolic steroids, heparin, anticonvulsants, fluoride in excess of 1 mg/day and supplements of vitamin d or a in excess of rdas. 4. vitamin d deficiency (1, 25-dihydroxyvitamin d is lower than the normal range of: 25.1 pg/ml \~ 66.1 pg/ml). 5. patients with fracture history. 6. patients who can not promise to keep from taking stimulant drinks (for example, coffee, tea, alcoholic drink, and coke) that may cause loss of bone calcium, during the study period.

Keywords: osteoporosis postmenopausal women botanical drug
peer-led trauma therapy for re-entry

Conditions: PTSD

Summary: the purpose of the research is to learn more about how to treat ptsd for people directly impacted by incarceration (i.e., have spent time in prison or jail). this research will help identify if a ptsd treatment group that is used in community settings, and led by individuals with lived experience, is helpful in reducing ptsd symptoms among people who have been directly impacted by incarceration. participants will complete an interview to determine whether they are experiencing ptsd, and if so, will participate in a 6-week therapy group treatment.

two community certified peer specialists (cpss) who have experienced incarceration and re-entry from prison, and who have experienced trauma will be trained on delivering group cognitive processing therapy (cpt). working with the wisconsin department of health services (dhs) and community organizations serving formerly incarcerated individuals, researchers will screen individuals for ptsd treatment need, and invite 48 eligible individuals to participate in group cpt co-led by one of the trained cpss and a trained community therapist or provider. eligible participants who are enrolled in the study will be invited to complete a 6-week (12 sessions total) group cpt therapy treatment for ptsd. participants will also complete pre-, mid-, and post-treatment mental health surveys. participants will also complete a post-treatment focus group or post-treatment individual interview where they are asked about their experience in the therapy and to provide feedback on the study as a whole.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * completed a prison or jail sentence * no current psychosis symptoms * no active self-harm or active suicidal intent * able and willing to participate in group therapy * meet criteria for ptsd treatment need exclusion criteria: * current and active psychosis * current and active self-harm and suicidality * no ptsd diagnosis * current substance use dependence (not including those used as prescribed for medical reasons) on alcohol, cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids

Keywords: previously incarcerated group therapy cognitive processing therapy
web-based training and telephone follow-up of patients with heart failure: randomized controlled trial

Conditions: Heart Failure; Patient; Quality of Life; Symptoms

Summary: web-based training and telephone monitoring have an effect on reducing symptom burden in patients with heart failure. web-based training and telephone monitoring have an effect on improving the quality of life of patients with heart failure. web-based training and telephone follow-up have an effect on reducing recurrent hospitalizations of patients with heart failure. web-based training and telephone follow-up have a positive effect on the clinical parameters (weight, waist circumference, blood pressure, creatinine) of patients with heart failure.

the aim of this study was to determine the effect of web-based training and telephone monitoring on symptom management and quality of life in patients with heart failure. study was conducted with the participation of 32 intervention and 32 control patients who have heart failure, in akdeniz university hospital cardiology clinic, between april 2018 and july 2019. data were collected using the patient information form, left ventricular dysfunction scale and memorial symptom rating scale-heart failure scale, website analysis and measurement inventory. the patients in the intervention group received web-based training after discharge, and were followed up by telephone at the first, fourth, eighth and 12 weeks. the scale data were collected before the patient was discharged from hospital and at the third month of discharge.

Eligibility criteria:
inclusion criteria: * undergoing treatment at the cardiology clinic of akdeniz university hospital with a diagnosis of heart failure. * class i, ii, iii according to nyha classification * has internet access and can use a computer / tablet or smartphone * agree to participate in the research exclusion criteria: * functional class iv according to nyha classification * diagnosed with psychiatric illness * malignancy diagnosed * visually and hearing impaired * diagnosed with chronic obstructive pulmonary disease

Keywords: heart failure web-based training telephone monitoring symptom assessment quality of life
comparing sms and e-mail reminders in an online smoking cessation intervention

Conditions: Nicotine Dependence Tobacco Product

Summary: the primary purpose of the current study is to compare the effect of sms-textmessage vs e-mail reminders on user engagement and proportion of reported quit attempts in an online smoking cessation intervention.

web- and mobile phone health behavior change interventions, including smoking cessation programs, offer great promise, but little is known about how such interventions should be designed to increase user engagement. the primary purpose of the current study is to compare the effect of sms-textmessage vs e-mail reminders on user engagement and proportion of reported quit attempts in an online smoking cessation intervention. the investigators propose a 2-arm rct with 700 adult study participants that all receive a best practices web-based smoking cessation program designed for use on smart phones (web-app). the intervention includes a ten day preparation phase, in which participants continue smoking. on the eleventh day (and onward) the user will receive a session in which (s)he is asked whether (s)he has quit smoking or not. if not, the user will receive additional treatment sessions until (s)he reports having quit (or dropped out of the study). each day (for up to 14 days) a new unique session is assigned to the user. however, if the user does not log on to the web-intervention and starts using the session by noon on the second day after assignment, the user will receive a reminder to do so. when a user is to be sent a reminder for the first time, (s)he will be randomized to either receive such reminders by sms or by e-mail. the primary outcome is reporting a quit attempt or not. secondary outcomes include number web-sessions started and completed and time spent navigating sessions after the first reminder is received.

Eligibility criteria:
inclusion criteria: * 18 years or older * current smoker * determined to or considering to quit smoking * provide valid e-mail address * provide valid norwegian cell phone number * complete a baseline questionnaire * start using the intervention (pushing the next page button one time or more on the first session provided) * has not logged on to any of the online session within noon on the second day after that particular session was made available exclusion criteria: * not starting the first treatment session * taking every treatment session on time (no need for reminders, and thus not randomized)

Keywords: online intervention e-health reminder sms-textmessage e-mail mobile phone cell phone
reading disability in children with nf1

Conditions: Neurofibromatosis Type 1

Summary: a national, multicenter, randomized, transverse clinical trial, estimating the existence of phonological deficits in children with nf1 children compared with control children without nf1 with the same reading level.

to determine the phonological and visio -spatial performances at the nf1 children.

Eligibility criteria:
inclusion criteria: * age included between 8 and 12 years * child presenting a type 1 neurofibromatosis according to 2 criteria in the following criteria list : * at least 6 café au lait spots * 2 or more neurofibromas or 1 plexiform neurofibroma * axillary or inguinal freckling * 1 optic nerf glioma * 2 or more lisch nodules * 1 osseous lesion as sphenoid dysplasia or thinning of the long bone cortex with or without pseudoarthrosis * 1 a first degree relative (parent, sibling, or offspring) with nf1 by the above criteria * membership in a national insurance * consent of the child and the parents exclusion criteria: * mental retardation (qi t \< 70) * treated or untreated epilepsy * visual deficit (visual acuteness \< 4/10 * presence of a symptomatic optic glioma * presence of a brain tumor.

Keywords: nf1 children reading disabilities